Roche Holding AG (OTCQX International Premier:RHHBY)

29.75
Delayed Data
As of Feb 23
 -0.10 / -0.34%
Today’s Change
28.48
Today|||52-Week Range
36.82
-5.79%
Year-to-Date
Shionogi's Single-Dose Flu Drug Gets Japanese Approval
Feb 23 / TheStreet.com - Paid Partner Content
Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses
Feb 15 / Zacks.com - Paid Partner Content
Will Mylan (MYL) Disappoint Investors This Earnings Season?
Feb 22 / Zacks.com - Paid Partner Content
Roche's Rituxan Gets Priority Review for Label Expansion
Feb 14 / Zacks.com - Paid Partner Content
Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?
Feb 21 / Zacks.com - Paid Partner Content
Exelixis Reports Positive Data From Thyroid Carcinoma Trial
Feb 14 / Zacks.com - Paid Partner Content
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)
Feb 16 / Zacks.com - Paid Partner Content
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
Feb 14 / Zacks.com - Paid Partner Content
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
Feb 16 / Zacks.com - Paid Partner Content
Pfizer Announces FDA Acceptance of NDA for NSCLC Candidate
Feb 13 / Zacks.com - Paid Partner Content
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan
Feb 16 / Zacks.com - Paid Partner Content
ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow
Feb 12 / Zacks.com - Paid Partner Content
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock
Feb 15 / Zacks.com - Paid Partner Content